http://www.francesoir.fr/opinions-e...ienne-sur-3-451-patients-confirme-lefficacite
An Italian study carried out on a group of more than 3,000 patients, hospitalized for Covid-19, concluded that "the use of hydroxycholoroquine is associated with a 30% reduction in mortality".
FS: How many patients are affected by your study?
LI: Our study (COVID-19 RISK and CORIST Collaboration Treatments) was carried out on a cohort of 3451 patients admitted to 33 clinical centers across Italy. This is a retrospective observational study.
FS: What structures are involved in collecting clinical data on patients?
LI: The study focused on 33 structures, among the most recognized and important in Italy: Gemelli, Humanitas, San Matteo di Pavia, San Donato, San Gerardo di Monza, Spallanzani, Cotugno di Napoli, Miulli di Acquaviva delle Fonti, Monzino . University of Napoli Federico II, Catania, Palermo, Cagliari, Chieti.
FS: It's a study involving Italian hospital structures, from North to South. What conclusions did you reach?
LI: We have seen a 30% decrease in the risk of death in patients receiving hydroxychloroquine. The inverse association of hydroxychloroquine with in-hospital mortality was particularly evident in patients with elevated C-reactive protein upon entry.
FS: What do you mean by “they had a high level of C-reactive protein on entry”?
LI: C-reactive protein is a marker of inflammation. Having a high level of C-reactive protein when entering the hospital means that the Sars-Covid II infection has caused a significant inflammatory response. We believe that HCQ acts on this very component of the disease rather than inhibiting viral replication.
FS: What were the mortality rates in the hydroxychloroquine and control groups?
LI: The mortality rate of patients receiving hydroxychloroquine was 8.9 / 1000 patients / day, the mortality rate of those not receiving hydroxychloroquine was 15.7 / 1000 patients / day. Treatment was started on the first day of admission in most clinical centers, at a dose of 400 mg once a day, for an average of 10 days.
76% of patients were on HCQ treatment .
FS: Did the drug have statistically significant side effects?
LI: Our study did not collect information on adverse effects. However, the studies already published by the different centers participating in our study did not show significant cardiovascular clinical events, although there was an increase in the ECG QT. (sources:
https://linkinghub.elsevier.com/retrieve/pii/S0167527320322233 and
https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.048476 )
Funny how the FDA's report differs so much compared to numerous other positive studies out there world wide. Especially regarding cardiac events. If you look into the details on what the FDA determined this on, you had hospitals giving 3x the daily amount that has had success. So yeah maybe there are adverse effects if you give someone way too much. That's how drugs can work. You have to figure out the middle ground and stay there.